← Leaderboards
Christopher Ryan Miller
University Of Alabama At Birmingham
$3,962,587
Attributed
$7,699,445
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,699,445 · 6
By mechanism
R01$5,518,677 · 3
P30$1,483,403 · 1
P01$583,666 · 1
U54$113,699 · 1
Top collaborators
- Frank Furnari7 shared
- Michael E. Berens4 shared
- Gary L. Johnson4 shared
- Donald M O'Rourke4 shared
- Hua Zhao1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Christopher D Willey$2,398,828
- Jake Yue Chen$4,305,293
- Xiangqin Cui$800,390
- G. Yancey Gillespie$5,456,344
- Frank Furnari$6,666,697
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResearch PersonnelHuman DiseaseMemberServicesTissue MicroarrayHuman ResourcesArchivesPublicationsUnited States National Institutes Of HealthLaboratoriesSurgical PathologyParaffin EmbeddingHistopathologyPre-ClinicalGrantFundingHospitalsFormalinAnimal TissueHuman TissueAnticancer ResearchMolecularHuman Pathology
Grant awards (26)
Therapeutic targeting mesenchymal transition in newly diagnosed and recurrent GBM$623,787
R01 · FY2025 · NS
Credentialing next-generation human glioma models for precision therapeutics$562,355
R01 · FY2025 · CA · contact PI
Therapeutic targeting mesenchymal transition in newly diagnosed and recurrent GBM$649,226
R01 · FY2024 · NS
Credentialing next-generation human glioma models for precision therapeutics$534,956
R01 · FY2024 · CA · contact PI
Credentialing next-generation human glioma models for precision therapeutics$556,011
R01 · FY2023 · CA · contact PI
Credentialing next-generation human glioma models for precision therapeutics$131,545
R01 · FY2023 · CA · contact PI
Credentialing next-generation human glioma models for precision therapeutics$618,530
R01 · FY2022 · CA · contact PI
Translational Pathology$299,148
P30 · FY2020 · CA · contact PI
Diagnostic and Molecular Histopathology Core$15,550
U54 · FY2020 · CA · contact PI
Credentialing murine models for glioblastoma preclinical drug development$472,269
R01 · FY2019 · CA · contact PI
Translational Pathology$289,966
P30 · FY2019 · CA · contact PI
Credentialing murine models for glioblastoma preclinical drug development$133,154
R01 · FY2019 · CA · contact PI
Diagnostic and Molecular Histopathology Core$18,818
U54 · FY2019 · CA · contact PI
Credentialing murine models for glioblastoma preclinical drug development$605,422
R01 · FY2018 · CA · contact PI
Translational Pathology$299,147
P30 · FY2018 · CA · contact PI
Diagnostic and Molecular Histopathology Core$22,034
U54 · FY2018 · CA · contact PI
Translational Pathology$2,968
P30 · FY2018 · CA · contact PI
Translational Pathology$2,102
P30 · FY2018 · CA · contact PI
Translational Pathology$1,367
P30 · FY2018 · CA · contact PI
Credentialing murine models for glioblastoma preclinical drug development$631,422
R01 · FY2017 · CA · contact PI
Translational Pathology$293,472
P30 · FY2017 · CA · contact PI
Diagnostic and Molecular Histopathology Core$13,740
U54 · FY2017 · CA · contact PI
Translational Pathology$295,233
P30 · FY2016 · CA · contact PI
Diagnostic and Molecular Histopathology Core$21,965
U54 · FY2016 · CA · contact PI
Diagnostic and Molecular Histopathology Core$21,592
U54 · FY2015 · CA · contact PI
Biospecimen: Genomics and Pathology$583,666
P01 · FY2011 · CA